Focused On-demand Library for Ubiquitin carboxyl-terminal hydrolase 8

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P40818

UPID:

UBP8_HUMAN

Alternative names:

Deubiquitinating enzyme 8; Ubiquitin isopeptidase Y; Ubiquitin thioesterase 8; Ubiquitin-specific-processing protease 8

Alternative UPACC:

P40818; B4DKA8; Q2TB31; Q7Z3U2; Q86VA0; Q8IWI7

Background:

Ubiquitin carboxyl-terminal hydrolase 8, also known as Deubiquitinating enzyme 8, plays a crucial role in protein turnover by removing conjugated ubiquitin, thus preventing degradation. It is involved in various cellular processes including cell proliferation, T-cell anergy regulation, and endosomal ubiquitin dynamics. Its activity is pivotal in maintaining the balance of protein ubiquitination, essential for cellular homeostasis and organelle morphology.

Therapeutic significance:

The protein's involvement in Pituitary adenoma 4, ACTH-secreting, through excessive adrenocorticotropic hormone production leading to Cushing syndrome, highlights its therapeutic significance. Understanding the role of Ubiquitin carboxyl-terminal hydrolase 8 could open doors to potential therapeutic strategies for treating this neuroendocrine tumor and its systemic manifestations.